---
title: "Psych News Alert: FDA Approves New Three-Month Long-Acting Antipsychotic Invega Trinza"
description: The FDA has approved Invega Trinza (paliperidone palmitate), a long-acting atypical antipsychotic intended to treat schizophrenia, from J...
---

 5/22/15 12:00 AM

# FDA Approves New Three-Month Long-Acting Antipsychotic Invega Trinza

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [ Psychiatric News Alert ](https://alert.psychnews.org/author/psychiatric-news-alert)

Share: [facebook-f icon ](http://www.facebook.com/share.php?u=https://alert.psychnews.org/2015/05/fda-approves-new-three-month-long.html) [linkedin-in icon ](http://www.linkedin.com/shareArticle?mini=true&url=https://alert.psychnews.org/2015/05/fda-approves-new-three-month-long.html) [Twitter icon ](https://twitter.com/intent/tweet?url=https://alert.psychnews.org/2015/05/fda-approves-new-three-month-long.html) [pinterest-p icon ](http://pinterest.com/pin/create/link/?url=https://alert.psychnews.org/2015/05/fda-approves-new-three-month-long.html) [envelope icon ](mailto:?body=https://alert.psychnews.org/2015/05/fda-approves-new-three-month-long.html)

| ![](https://static.hsstatic.net/BlogImporterAssetsUI/ex/missing-image.png) |  |
| --- | --- |

The FDA has approved Invega Trinza (paliperidone palmitate), a long-acting atypical antipsychotic intended to treat schizophrenia, from Janssen Pharmaceuticals Inc.

The approval of the injectable antipsychotic, which remains active in the body for three months, was based on results from a two-year maintenance trial with 506 patients diagnosed with schizophrenia. The [analysis](http://archpsyc.jamanetwork.com/article.aspx?articleid=2211343), published March 29 in *JAMA Psychiatry*, showed that patients who were administered Invega Trinza were statistically less likely to relapse than those who were administered placebo. The most common adverse effects of the medication included injection-site reactions, weight gain, upper respiratory tract infections, and extrapyramidal symptoms.

The newly approved antipsychotic will come with a boxed warning stating that it is not approved for patients with dementia-related psychosis and that use of the drug may increase the risk for death in elderly patients with dementia.

Before patients can begin taking Invega Trinza, they must first show tolerability to Janssen's Invega Sustenna, a one-month form of paliperidone palmitate, for at least four months.

Invega Trinza was approved under the FDA's priority review process, a fast track for drugs thought to represent a significant advance in medical care. It is being marketed by Janssen.

For more information about psychotropic medications in the pipeline, see the *Psychiatric News* article "[Candidates, Innovation Missing From Psychotropic Drug Pipeline](http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2014.11a2)."

[FDA approval](https://alert.psychnews.org/tag/fda-approval), [long-acting injectable antipsychotics](https://alert.psychnews.org/tag/long-acting-injectable-antipsychotics)

## Related posts

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/iStock-483968360-4.jpg?height=200&name=iStock-483968360-4.jpg) ](https://alert.psychnews.org/2017/02/lai-aripiprazole-may-reduce-recurrence.html)

[aripiprazole](https://alert.psychnews.org/tag/aripiprazole), [bipolar disorder](https://alert.psychnews.org/tag/bipolar-disorder), [long-acting injectable antipsychotics](https://alert.psychnews.org/tag/long-acting-injectable-antipsychotics)

## [LAI Aripiprazole May Reduce Recurrence of Mood Episodes in Patients With Bipolar I Disorder](https://alert.psychnews.org/2017/02/lai-aripiprazole-may-reduce-recurrence.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 2/1/17 12:00 AM

Treating patients with bipolar I disorder with a once-monthly long-acting injectable (LAI) form of...

[ Read more ](https://alert.psychnews.org/2017/02/lai-aripiprazole-may-reduce-recurrence.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/shutterstock_182778842-Jun-24-2025-05-25-14-9791-PM.jpg?height=200&name=shutterstock_182778842-Jun-24-2025-05-25-14-9791-PM.jpg) ](https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html)

[schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [long-acting injectable](https://alert.psychnews.org/tag/long-acting-injectable), [relapse](https://alert.psychnews.org/tag/relapse), [JAMA Psychiatry](https://alert.psychnews.org/tag/jama-psychiatry), [Paliperidone palmitate](https://alert.psychnews.org/tag/paliperidone-palmitate)

## [Three-Month Form of Paliperidone Reduces Relapse in Schizophrenia, Study Shows](https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 3/31/15 12:00 AM

A three-month formulation of paliperidone palmitate administered four times yearly as a long-acting...

[ Read more ](https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/shutterstock_143531137-Jun-24-2025-04-40-23-3879-PM.jpg?height=200&name=shutterstock_143531137-Jun-24-2025-04-40-23-3879-PM.jpg) ](https://alert.psychnews.org/2015/04/brexpiprazole-found-safe-effective-for.html)

[schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [ajp in advance](https://alert.psychnews.org/tag/ajp-in-advance), [brexpiprazole](https://alert.psychnews.org/tag/brexpiprazole)

## [Brexpiprazole Found Safe, Effective for Patients With Schizophrenia, AJP Reports](https://alert.psychnews.org/2015/04/brexpiprazole-found-safe-effective-for.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 4/17/15 12:00 AM

New findings from a phase 3 clinical trial, published today in AJP in Advance, suggest that a...

[ Read more ](https://alert.psychnews.org/2015/04/brexpiprazole-found-safe-effective-for.html)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Psychiatric News Alert",
    "url" : "https://alert.psychnews.org/author/psychiatric-news-alert"
  },
  "dateModified" : "2025-06-24T15:25:47.486Z",
  "datePublished" : "2015-05-22T04:00:00.000Z",
  "headline" : "Psych News Alert: FDA Approves New Three-Month Long-Acting Antipsychotic Invega Trinza",
  "mainEntityOfPage" : {
    "@id" : "https://alert.psychnews.org/2015/05/fda-approves-new-three-month-long.html",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://alert.psychnews.org/hubfs/PN-Blue-Box.jpg"
    }
  }
}
```